
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$3.20
+US$0.00 · +0.00%
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
常规交易时段
US$3.20
+US$0.00 · +0.00%
盘中时间采用ET。市场数据可能有所延迟。
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
日内区间
当前US$3.20
52周区间
当前US$3.20
盘中时间采用ET。市场数据可能有所延迟。
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
日内区间
当前US$3.20
52周区间
当前US$3.20
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1878.9万 USD | 1416.2万 USD | 1423.8万 USD | 997.5万 USD | 1021.7万 USD |
| 销货成本 | 730.4万 USD | 543.9万 USD | 583.3万 USD | 524.4万 USD | 458.4万 USD |
| 毛利 | 1148.5万 USD | 872.3万 USD | 840.5万 USD | 473.1万 USD | 563.3万 USD |
| 研究与开发 | 133.9万 USD | 90.6万 USD | 87.3万 USD | 125.5万 USD | 149.8万 USD |
| 销售、一般及管理费用 | 900万 USD | 767.6万 USD | 891.1万 USD | 759.3万 USD | 719.5万 USD |
| 营业费用 | 1033.9万 USD | 871.7万 USD | 999.8万 USD | 906.6万 USD | 888.5万 USD |
| 利息收入 | 13.9万 USD | 9.4万 USD | 6.4万 USD | 1.4万 USD | 1万 USD |
| 利息支出 | 1000 USD | 1000 USD | 2000 USD | 2万 USD | 4.1万 USD |
| 折旧和摊销 | 13.9万 USD | 13.7万 USD | 21.4万 USD | 35.1万 USD | 25.2万 USD |
| 营业利润 | 114.6万 USD | 6000 USD | −159.3万 USD | −433.5万 USD | −325.2万 USD |
| 净利润 | 119.4万 USD | 7.4万 USD | −157.5万 USD | −738.2万 USD | −410.7万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$4.00
上涨空间 25.00%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2019年7月10日 | 1:9 | — | — |
股票拆分 | 2011年3月17日 | 1:20 | — | — |
已生效 2019年7月10日
1:9
已生效 2011年3月17日
1:20
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI56.03万0.00%2.3万亿 USD0.03%US$378.46-0.67%
Vanguard Extended Market ETFVXF28.99万0.00%954亿 USD0.05%US$232.33-0.50%
iShares Micro-Cap ETFIWC5.38万0.00%13.33亿 USD0.60%US$182.4-0.53%
Dimensional - US Core Equity 2 ETFDFAC2.28万0.00%882.76亿 USD0.21%US$45.005-0.39%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.45万0.00%454.32亿 USD0.17%US$83.895-0.24%
U.S. Vector Equity Portfolio ETF Class SharesDXUV4285.380.00%61.57亿 USD0.26%US$67.985+0.04%
Dimensional - US Sustainability Core 1 ETFDFSU1308.80.00%23.81亿 USD0.15%US$47.725-0.41%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Dimensional - US Core Equity 2 ETFDFAC
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR
U.S. Vector Equity Portfolio ETF Class SharesDXUV
Dimensional - US Sustainability Core 1 ETFDFSUAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。